AIL
ACAD icon

AGF Investments LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

AGF Investments LLC’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-32,877
Closed -$796K – 384
2022
Q1 		$796K Sell
32,877
-8,417
-20% -$204K 0.07% 202
2021
Q4 		$964K Buy
41,294
+4,110
+11% +$82.7K 0.08% 52
2021
Q3 		$618K Buy
37,184
+8,758
+31% +$169K 0.06% 121
2021
Q2 		$693K Buy
+28,426
New +$642K 0.07% 73
2020
Q3 		– Sell
-464
Closed -$22K – 547
2020
Q2 		$22K Buy
464
+277
+148% +$13.3K ﹤0.01% 461
2020
Q1 		$8K Buy
187
+54
+41% +$2.23K ﹤0.01% 488
2019
Q4 		$6K Sell
133
-268
-67% -$11.7K ﹤0.01% 519
2019
Q3 		$14K Buy
401
+99
+33% +$3K ﹤0.01% 474
2019
Q2 		$8K Buy
+302
New +$7.71K ﹤0.01% 537
2018
Q1 		– Sell
-300
Closed -$9K – 650
2017
Q4 		$9K Buy
300
+46
+18% +$1.47K ﹤0.01% 554
2017
Q3 		$10K Sell
254
-108
-30% -$3.51K ﹤0.01% 490
2017
Q2 		$10K Buy
362
+82
+29% +$2.44K ﹤0.01% 460
2017
Q1 		$10K Sell
280
-64
-19% -$2.26K ﹤0.01% 466
2016
Q4 		$10K Buy
+344
New +$9.1K ﹤0.01% 560

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AGF Investments LLC's ACAD Position: Q2 2022 in Review

AGF Investments LLC sold out of Acadia Pharmaceuticals (ACAD) in Q2 2022, closing a stake of 32,877 shares — an estimated $796K sold.

AGF Investments LLC first reported a position in ACAD in Q4 2016 and held it in 14 quarters. The position peaked at $964K in Q4 2021. 246 funds tracked by Wall St. Rank hold ACAD as of Q2 2022.

  • AGF Investments LLC reported no remaining Acadia Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • AGF Investments LLC sold 32,877 Acadia Pharmaceuticals shares in Q2 2022, an estimated $796K.
  • AGF Investments LLC first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 14 quarters.
  • AGF Investments LLC's Acadia Pharmaceuticals position peaked at $964K in Q4 2021.
  • 246 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2022.

Based on AGF Investments LLC's 13F filing for Q2 2022, filed 12 Aug 2022.